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During and after coronary artery bypass grafting (CABG), oxidative stress occurs. Finding an effective way to improve antioxidant
response is important in CABG surgery. It has been shown that patients with coronary heart disease have a low Melatonin
production rate.Thepresent study aimed to investigate the effects ofMelatonin onnuclear erythroid 2-related factor 2 (Nrf2) activity
in patients undergoing CABG surgery. Thirty volunteers undergoing CABG were randomized to receive 10mg oral Melatonin
(Melatonin group, 𝑛 = 15) or placebo (placebo group, 𝑛 = 15) before sleeping for 1 month before surgery. The activated Nrf2
was measured twice by DNA-based ELISA method in the nuclear extract of peripheral blood mononuclear cells of patients before
aortic clumps and 45 minutes after CABG operation. Melatonin administration was associated with a significant increase in both
plasma levels of Melatonin and Nrf2 concentration inMelatonin group compared to placebo group, respectively (15.2±4.6 pmol/L,
0.28 ± 0.01 versus 1.1 ± 0.59 pmol/L, 0.20 ± 0.07, 𝑃 < 0.05). The findings of the present study provide preliminary data suggesting
that Melatonin may play a significant role in the potentiation of the antioxidant defense and attenuate cellular damages resulting
from CABG surgery via the Nrf2 pathway.
1. Introduction
Myocardial ischemia-reperfusion injury (IRI) represents a
clinically critical problem associated with coronary artery
bypass surgery (CABG) [1, 2]. Reactive oxygen species,
including superoxide radical, hydroxyl radical, and hydrogen
peroxide are considered to increase during reperfusion of the
heart following ischemia [2]. Systemic increase of hydrogen
peroxide and lipid peroxidation products has been shown
to occur during CABG operation [3]. The contact of the
circulating blood to nonphysiological surfaces during CABG
may be another potential source of oxidative stress [4]. Cell
death secondary to IRI occurs during the first minutes after
restoration of blood flow [5].
Despite improvements in anesthesia management, surgi-
cal technique, and postoperative care, CABGwith cardiopul-
monary bypass is associated with oxidative stress so it is
important to reduce the effect of reactive oxygen species dur-
ing CABG and find an effective way to improve antioxidant
response against IRI [6].
Melatonin (N-acetyl-5-methoxytryptamine) is synthe-
sized from tryptophan and secreted principally by the
pineal gland [7, 8]. It has an endogenous circadian rhythm
of secretion induced by the suprachiasmatic nuclei of
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the hypothalamus [9]. In mammals, Melatonin is present in
almost all tissues, with or without the Melatonin receptors,
because it acts both as a hormone and an antioxidant [10].
Melatonin is a highly lipophilic molecule that crosses
cell membranes to easily reach subcellular compartments
including mitochondria [11]. It stabilizes mitochondria inner
membranes [12] and reduces electron leakage and generation
of free radicals [13]. Furthermore,Melatonin has potent direct
peroxyl radical-scavenging activities [14].
The efficacy of Melatonin as an antioxidant agent relates
to its direct actions in scavenging free radicals, and also
its potential ability to enhance the activities of a variety of
antioxidative enzymes, for instance, its stimulatory effects
on the synthesis of glutathione (which is also an important
antioxidant) [14]. Melatonin is several times more effective
in scavenging the extremely toxic hydroxyl radical than glu-
tathione and mannitol and twice as efficient as vitamin E in
detoxifying the peroxyl radical [12, 13].
Several recent experimental studies have linked the ben-
eficial effects of Melatonin in ischemia-reperfusion injuries
to nuclear factor (erythroid-derived 2)-like 2, also known
as NFE2L2 or Nrf2 pathway activation [15, 16]. Nrf2 is a
transcription factor which is responsible for the regulation
and management of many antioxidant response genes in
cells through binding with DNA antioxidant response ele-
ment (ARE) [17]. Under normal conditions, Nrf2 is found
mainly sequestered in the cytoplasm, tethered by a protein
called Keap1; several stimuli can translocate Nrf2 from
the cytoplasm to the nucleus. After binding to ARE,
Nrf2 transactivates the expression of a group of cyto-
protective enzymes, such as heme oxygenase-1 (HO-1),
NAD(P)H:quinone oxidoreductase-1 (NQO1), and glutathi-
one S-transferase 𝛼-1 (GST-𝛼1) [18]. Nrf2-ARE pathway is
considered to be a main protector and reported to play an
important role in ischemia-reperfusion injury [19]. So, it can
be considered as a master regulator of antioxidant defense
pathway.
The collective results showed that patients undergoing
CABG are at risk of free radical damage. Furthermore, it
has been shown that Melatonin secretion is reduced in coro-
nary heart disease (CHD) [9, 20]. Melatonin administration
against these conditions are due to its direct free radical
scavenger activity.
In regard to the beneficial effects of Melatonin to induce
activation of Nrf2 as an oxidative stress-sensing guarding
regulator leading to expression of important ARE-driven
genes such as NQO1, HO-1, SOD2, and GST and, in finding
an effective clinical strategy for abrogating reperfusion injury,
the purpose of this study was to investigate the potential
protective effect of Melatonin against IRI in CABG surgery
through the activation ofNrf2 as a critical transcription factor
for antioxidant defense management at cellular level.
2. Materials and Methods
Forty volunteers who were undergoing elective CABG were
enrolled in a randomized triple-blind placebo-controlled
study. After obtaining approval from the ethics committee of
Isfahan University of Medical Sciences and written informed
consent, we excluded from the study patients that need
emergency operation and have not enough time to use
tablets for 1 month, elderly patients (>75 years), reoperations,
patients with coexisting renal insufficiency, patients with
serious pulmonary disease, those with prior stroke or signif-
icant cerebrovascular disease, and patients with an ejection
fraction <40%. Patients undergoing CABGwith concomitant
heart valve repair or replacement, resection of a ventricular
aneurysm, or other surgical procedures were also excluded.
We included in the study 52 patients who were to undergo
elective CABG. The patients were assigned into 2 groups
randomly.The patients in group I (𝑛 = 15) underwent CABG
with administration of 10mg tablet (Melatonin,NatureMade,
CA,USA) (Melatonin group) before sleeping for 1month, and
the patients in Group II (𝑛 = 15) underwent their operations
with the usage of placebo in the same course. Flow diagram
of patients participation in the study is shown in Figure 1.
According to the previous studies, the effective dosage
of Melatonin to reduce oxidative stress related to surgical
procedures was 10mg/kg [21–23].
Patients were allocated in Melatonin or placebo group,
using a random number table, to receive either 10mg oral
Melatonin (Melatonin, Nature Made, CA, USA) or placebo
1 month before surgery approximately 1 hour before sleeping.
Blinding and randomization were performed by two investi-
gators not involved in the patients’ evaluations.
All of the operations in each group started at the same
time, and all of the patients in the study underwent their oper-
ationswith the same technique and by the same surgical team.
The operations started regularly at 1–6 PM. All of the patients
received the same cardiac drug regimen before the oper-
ation, generally angiotensin-converting enzyme inhibitors,
𝛽-blockers, vasodilators, lipid-lowering agents, aspirin, or
heparin.
2.1. Surgical Technique. Patients underwent their operations
on cardiopulmonary bypass with routine ascending-aorta
and right-atrial cannulation. The core temperature was
allowed to drift to 32∘C, and aortic venting was performed.
Myocardial protection was provided with antegrade and
intermittent retrograde cold blood cardioplegia. Distal and
proximal anastomoses were completed in a single aortic
cross-clamp period.
2.2. Blood Sampling and Analysis. Blood samples were col-
lected at the beginning of the study, before the administration
ofMelatonin or placebo (T1), after one-month administration
of Melatonin or placebo just before operation (T2), when the
aortic cross-clamp was placed (T3), and 45 minutes after the
operation (T4).
Plasma concentrations of Melatonin were measured in
duplicate by using Enzyme-Linked Immunoassay (IBL Inter-
national, Germany). The intra-assay coefficient of variation
was 6.7%.
Melatonin levels in serum samples of (T1) and (T2) were
measured with an enzyme immunoassay for the quantitative
determination in human serum kit (IBL International, Ham-
burg, Germany).





19 because of not meeting inclusion criteria
15 because of refusing to participate
29 patients received Melatonin
Followup
29 patients received placebo
5 patients discontinued intervention
because emergency operation
9 patients excluded because of “poor
compliance” or “irregular intake”
15 patients were analyzed15 patients were analyzed
3 patients discontinued intervention
because of emergency operation
11 patients excluded because of “poor
compliance” or “irregular intake”
92 patients assessed for eligibility
34 patients were excluded
Figure 1: flow diagram of patients participation in the study.
Blood samples were collected from the central venous
line before the aortic cross-clamp was placed (T3) and at 45
minutes after the operation (T4).
Ten mL of blood was collected from each subject in a
sterile glass tube containing 100 IU of preservative-free hep-
arin (Sigma, St. Louis, MO, USA) at each of the time points
described.
TwomL of the each blood sample was immediately cen-
trifuged at 4000 rpm for 10 minutes and then were aliquot
and stored at −70∘C in average for 3 months in order to
analyze all samples simultaneously in the same procedure
conditions. 8mL of blood sample was used to isolate periph-
eral blood mononuclear cells (PBMCs) using the standard
Ficoll-Hypaque (Histopaque, Sigma) density gradient cen-
trifugation method. PBMCs were washed with PBS and
immediately placed in –70∘C and frozen for later analysis.
Once PBMCs for all 30 subjects were collected, after prepare
nuclear extraction by use of active motif kit, Nrf2 protein
analysis was performed using TransAM Nrf2 kits (Active
Motif, Carlsbad, CA, USA) which is an ELISA-based assay
with Nrf2alpha-specific antibodies.
Protein total of both samples of (T3) and (T4) was
measured by ZiestChem total protein kit which is based on
Biuret method.
2.3. Statistical Analysis. Statistical analysis was performed
with SPSS statistical software (version 11.0; SPSS, Chicago,
IL, USA). The results were analyzed to verify the normal-
ity of distribution using the test of Kolmogorov-Smirnov.
Continuous variables were expressed as the mean ± SD, and









Male/female sex, 𝑛 14/1 12/3 NS
Age, 𝑦 58.1 ± 9.8 60.1 ± 9.2 NS
Hypertension, 𝑛 8 7 NS
Diabetes mellitus type I or II, 𝑛 4 4 NS
Acute myocardial infarction 0 0 NS
Ejection fraction, % 58.5 ± 7.2 56.5 ± 4.6 NS
∗Data are presented as the mean ± SD, where indicated. NS: not statistically
significant.
differences were evaluated statistically with the Student’s 𝑡-
test for independent samples. 𝑃 value < 0.05 was considered
statistically significant.
3. Results and Discussion
The patients demographic data are summarized in Table 1.
Melatonin group (Group I) consisted of 14men and 1 women,
with a mean age of 58.1 ± 9.8 years (range, 42–75 years).
Placebo group (Group II) consisted of 12 men and 3 women,
with a mean age of 60.1 ± 9.2 years (range, 41–75 years). The
2 groups were not significantly different with respect to sex,
age, additional diseases (hypertension, diabetes mellitus), or
ejection fraction. None of the patients had acute myocardial
infarction.
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Table 2: The plasma levels of Melatonin and the intracellular levels of Nrf2 in different sampling session during the study.
Variable/sampling time Group I (Melatonin) Group II (placebo) 𝑃† 𝑃‡
Melatonin, pg/mL
𝑇1 2.11 ± 1.06 1.63 ± 0.88 NS 0.008 (Group I)
𝑇2 15.2 ± 4.6 1.1 ± 0.59 <0.001 NS (Group II)
NRF2/protein total
𝑇3 0.2819 ± 0.15 0.2092 ± 0.07 <0.05 NS (Group I)
𝑇4 0.2693 ± 0.09 0.1998 ± 0.04 <0.01 NS (Group II)
∗Data are presented as themean± SD. Sampling times were before the administration ofMelatonin or placebo (𝑇1), operation, after one-month administration
of Melatonin or placebo (𝑇2) before the aortic cross-clamp was placed (𝑇3), and 45 minutes (𝑇4) after the operation.
†
𝑃 values for the difference between groups I and II at the same time point.
‡
𝑃 values determined by paired 𝑡-test for differences at consecutive time points between groups.
Table 3: Perioperative and postoperative data of the patients∗.
Variable/sampling time Group I (Melatonin) Group II (placebo) 𝑃† 𝑃‡
Cross-clamp time, min 49.7 ± 18.4 42.7 ± 5.0 NS NA
CPB time, min 65.0 ± 10.1 70.6 ± 8.7 NS NA
Po2
𝑇3 349 ± 66.6 323 ± 44.4 NS <0.001 (Group I)
𝑇4 63.1 ± 14.1 42.4 ± 4.8 NS <0.001 (Group II)
O2 sat
𝑇3 75.4 ± 11.2 79.7 ± 9.8 NS NS
𝑇4 71.4 ± 22.7 62.8 ± 15.2 NS <0.05 (Group II)
Pco2
𝑇3 39.2 ± 6.1 42.0 ± 220 NS <0.05 (Group I)
𝑇4 45.8 ± 8 45.7 ± 4.3 NS NS
𝑇3 28.8 ± 5.6 27.3 ± 5.6 NS NS
𝑇4 27.2 ± 2 27.3 ± 2.1 NS NS
∗Data are presented as the mean ± SD. Sampling times were preoperatively before the aortic cross-clamp was placed (𝑇3) and at 45 min (𝑇4) postoperatively.
NS: not statistically significant; CPB: cardiopulmonary bypass; and NA: not applicable.
†
𝑃 values for the difference between groups I and II at the same time point.
‡
𝑃 values determined by paired 𝑡-test for differences at consecutive time points between groups.
Tables 2 and 3 summarize the perioperative and postop-
erative results of the patients.
At the beginning of the study, there were no significant
different levels of Melatonin between 2 groups of patients
while after 1-month Melatonin treatment the preoperative
plasma levels of Melatonin (T2) were substantially higher in
Melatonin group than in placebo group.
NRF2/protein total ratio was also significantly higher in
Melatonin group than in placebo group (𝑃 < 0.05) (Table 2).
Aortic cross-clamp and cardiopulmonary bypass times for
the 2 groups were similar (Table 3).
In the current study, we showed significant increase in
Nrf2 levels in Melatonin-treated group compared with con-
trols after CABG operation. The CABG surgery represents
an oxidative stress status with possible harmful effects for the
patients.TheCHDpatients are particularly prone to oxidative
damage because of their reduced antioxidant defense [24, 25].
In the current study, we tested for the first time whether
Melatonin would induceNrf2 as amaster transcription factor
formanagement of the oxidative stress in patients undergoing
CABG surgery.
Melatonin can control oxidative stress status through
different mechanisms. This molecule is a direct free radical
scavenger; it induces antioxidative enzymes and inhibits
proxoxidative enzyme; Melatonin stabilizes cell membrane
and increases the efficiency of mitochondrial oxidative phos-
phorylation [26]. Besides, several clinical and experimental
studies have confirmed that Melatonin has low toxicity [27].
Themechanisms bywhichMelatonin induced the expres-
sion of Nrf2 are not investigated in this study. However,
based on previous studies, at least four major mechanisms
are involved in the actions of Melatonin, including binding
to membrane receptors [28], binding to nuclear receptors
[29], interactions with cytoplasmic proteins [30], and direct
scavenging free radicals [31].
The mechanisms that underlie the effects of preoperative
Melatonin on postoperative outcomes are unclear, but several
experimental studies have demonstrated the beneficial effects
of Melatonin in several conditions associated with IRI.
Salie et al. [32] reported that Melatonin protects rat
ventricular myocytes injury against IRI, through inhibition
of reactive oxygen species generation and intracellular Ca2+
accumulation.
Tan et al. [33] found that Melatonin infusion throughout
the period of occlusion and after reopening of the coronary
artery in a Langendorff rat heart model significantly reduced
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both premature ventricular contractions and the ventricular
fibrillation.
Lagneux et al. [34] showed that Melatonin’s free radical
scavenging activity reduces infarct volume after IRI and
restores cardiac function. Additional investigations [35–38]
have confirmed the ameliorative effects of pharmacologic
doses ofMelatonin on cardiac tissue injury and function after
IRI.
The beneficial effects of Melatonin may derive from
its stimulatory effect on antioxidative enzymes including
superoxide dismutase, glutathione peroxidase, glutathione
reductase, and glucose-6 phosphate dehydrogenase and its
inhibitory action on the prooxidative inducible NO synthase
[39].
Dobsak et al. [40] showed that Melatonin can suppress
apoptosis and scavenge the peroxyl radical in a rat experi-
mental model of ischemia-reperfusion injury.
In the present research, we found that Nrf2-ARE pathway
could be further upregulated by the administration of Mela-
tonin in patients undergoing CABG.
In similar researches regarding the association of Mela-
tonin and Nrf2-ARE pathway, Crespo et al. [41] examined
the effects of Melatonin on oxidative stress and Nrf2-ARE
pathway in an animal model of fulminant hepatic failure.
They found thatMelatonin treatment resulted in an increased
protein expression of Nrf2 in the cytoplasm and the nucleus
and played a potential hepatoprotective role in fulminant
hepatic failure, partly mediated through the abrogation of
oxidative stress and the prevention of the decreased activity
of antioxidant enzymes via the Nrf2-ARE pathway. Similarly,
as mentioned by Tripathi and Jena [42] in their literature,
they investigated the influence of Melatonin on urotoxicity
associated with cyclophosphamide chemotherapy in patients
with cancer and found that Melatonin treatment favor-
ably changed Nrf2 expression, which appeared to be, at
least in part, responsible for observed protection against
cyclophosphamide-induced urotoxicity.
4. Conclusions
In the present research, we found that administration of
Melatonin in patients undergoing CABG can upregulate the
activity of Nrf2-ARE pathway with many potential beneficial
effects. Further studies with larger sample size and over a
longer period of time in patients are warranted to delineate
the role of Melatonin in reducing postoperative oxidative
stress in response to surgery. The mechanisms of Melatonin’s
effect in activation of Nrf2 and regulation of some other
transcription factors could be further investigated.
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